Catheterization Laboratory, Alexandra General Hospital, Athens, Greece.
HealThink (Medical Research & Innovation PC), Thessaloniki, Greece.
Hellenic J Cardiol. 2022 Sep-Oct;67:1-8. doi: 10.1016/j.hjc.2022.03.003. Epub 2022 Mar 17.
Acute myocardial infarction (AMI) is one of the leading causes of death; however, updated data regarding clinical presentation and current management are missing in Greece. This study aimed to prospectively record the demographic and clinical characteristics of a representative sample of patients suffering from AMI, their management, and short-term outcomes.
ILIAKTIS is a national, prospective, multicenter, noninterventional study conducted under the auspices of Hellenic Society of Cardiology (HCS) and the European Initiative Stent - Save a Life. From 1 April 2020 to 30 June 2020, consecutive adult patients with STEMI or NSTEMI were enrolled in the 50 participating hospitals, appropriately selected to match the geographical and population distribution in the Greek territory.
In total, 1862 patients (mean age: 64.2 ± 13.2 yrs.; 77.2% males) with AMI were enrolled. More patients presented with NSTEMI (56.8%) than with STEMI (43.2%). Primary PCI (pPCI) was the preferable treatment option for STEMI patients in PCI-hospitals (76.9% vs. 39.9% for non-PCI, p < .001) and thrombolysis in non-PCI-hospitals (47.3% vs. 17.9% for PCI-hospitals, p < .001). The mean length of hospital stay was 5.6 days. In-hospital mortality was less likely in NSTEMI compared to that in STEMI patients (aOR = 0.30; 95% CI 0.18 to 0.49). Patients initially admitted in non-PCI-hospitals showed increased risk for in-hospital (aOR = 2.29; 95% CI 1.20 to 4.42) and 30-day mortality (aOR = 1.88; 95% CI 1.20 to 2.96).
This study shows that the proportion of STEMI and NSTEMI patients managed interventionally has significantly increased, resulting in better clinical outcomes compared to previous Greek surveys.
急性心肌梗死（AMI）是导致死亡的主要原因之一；然而，希腊缺乏关于其临床表现和当前治疗方法的最新数据。本研究旨在前瞻性地记录代表性 AMI 患者的人口统计学和临床特征、他们的治疗方法以及短期预后。
ILIAKTIS 是一项全国性、前瞻性、多中心、非干预性研究，由希腊心脏病学会（HCS）和欧洲支架保存生命倡议赞助。从 2020 年 4 月 1 日至 6 月 30 日，连续入选符合条件的成年 STEMI 或 NSTEMI 患者，这些患者在希腊各地的 50 家参与医院中适当选择，以匹配地理和人口分布。
共纳入 1862 例 AMI 患者（平均年龄：64.2±13.2 岁；77.2%为男性）。与 STEMI 相比，更多患者表现为 NSTEMI（56.8% vs. 43.2%）。在 PCI 医院中，pPCI 是 STEMI 患者首选的治疗方法（76.9% vs. 非 PCI 医院的 39.9%，p<.001），而非 PCI 医院中溶栓治疗（47.3% vs. PCI 医院的 17.9%，p<.001）。平均住院时间为 5.6 天。与 STEMI 患者相比，NSTEMI 患者住院期间死亡率较低（aOR=0.30；95%CI 0.18 至 0.49）。最初在非 PCI 医院就诊的患者，住院期间（aOR=2.29；95%CI 1.20 至 4.42）和 30 天死亡率（aOR=1.88；95%CI 1.20 至 2.96）风险增加。
本研究表明，接受介入治疗的 STEMI 和 NSTEMI 患者比例显著增加，与以前的希腊调查相比，临床结局更好。
